These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26807922)

  • 1. Mutations Related to Antiretroviral Resistance Identified by Ultra-Deep Sequencing in HIV-1 Infected Children under Structured Interruptions of HAART.
    Vazquez-Guillen JM; Palacios-Saucedo GC; Rivera-Morales LG; Garcia-Campos J; Ortiz-Lopez R; Noguera-Julian M; Paredes R; Vielma-Ramirez HJ; Ramirez TJ; Chavez-Garcia M; Lopez-Guillen P; Briones-Lara E; Sanchez-Sanchez LM; Vazquez-Martinez CA; Rodriguez-Padilla C
    PLoS One; 2016; 11(1):e0147591. PubMed ID: 26807922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance mutations during structured interruptions of HAART in two HIV-1-infected children.
    Palacios-Saucedo GC; Rivera-Morales LG; Vázquez-Guillén JM; Sánchez LM; Ramírez TJ; Briones E; Ortiz-López R; Vázquez CA; Rodríguez-Padilla C
    Curr HIV Res; 2011 Apr; 9(3):154-9. PubMed ID: 21457133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.
    Arnedo-Valero M; Garcia F; Gil C; Guila T; Fumero E; Castro P; Blanco JL; Miró JM; Pumarola T; Gatell JM
    Clin Infect Dis; 2005 Sep; 41(6):883-90. PubMed ID: 16107990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.
    Kyeyune F; Gibson RM; Nankya I; Venner C; Metha S; Akao J; Ndashimye E; Kityo CM; Salata RA; Mugyenyi P; Arts EJ; Quiñones-Mateu ME
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3380-97. PubMed ID: 27001818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
    Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
    Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
    Chiappini E; Galli L; Zazzi M; de Martino M
    J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
    Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights about minority HIV-1 strains in transmitted drug resistance mutation dynamics and disease progression.
    Leda AR; Hunter J; Oliveira UC; Azevedo IJ; Sucupira MCA; Diaz RS
    J Antimicrob Chemother; 2018 Jul; 73(7):1930-1934. PubMed ID: 29684141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.
    Le T; Chiarella J; Simen BB; Hanczaruk B; Egholm M; Landry ML; Dieckhaus K; Rosen MI; Kozal MJ
    PLoS One; 2009 Jun; 4(6):e6079. PubMed ID: 19562031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults.
    Pai NP; Tulsky JP; Lawrence J; Colford JM; Reingold AL
    Cochrane Database Syst Rev; 2005 Oct; (4):CD005482. PubMed ID: 16235406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.
    Metzner KJ; Bonhoeffer S; Fischer M; Karanicolas R; Allers K; Joos B; Weber R; Hirschel B; Kostrikis LG; Günthard HF;
    J Infect Dis; 2003 Nov; 188(10):1433-43. PubMed ID: 14624368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
    Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
    Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between primary antiretroviral resistance and HAART virologic failure in a developing set.
    Gagliani LH; Alkmim Maia WT; Sá-Filho D; Janini LM; Sucupira MC; Caseiro MM; Diaz RS
    AIDS Res Hum Retroviruses; 2011 Mar; 27(3):251-6. PubMed ID: 20977353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.
    de Mulder M; Yebra G; Navas A; Martin L; de Jose MI; Navarro ML; de Ory SJ; Gonzalez-Granado I; Mellado MJ; Ramos JT; Holguin A
    Pediatr Infect Dis J; 2012 Nov; 31(11):e213-21. PubMed ID: 22785049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.